12-24 Month Healthy Children RSV Study
Participants needed: 12-24 months old
RSV is a germ that can cause airway infections. Most RSV infections just result in symptoms similar to a simple cold (such as a runny nose, sneezing and cough). However, RSV infection can be more serious in young babies, whose airways are still very small and whose immune system cannot fight germs very well. RSV is the cause of most bronchiolitis (infection of the breathing tubes causing wheezing) and some pneumonia (lung infection) in young infants. It is estimated that 31 babies out of 1000 under 6 months of age need to be admitted to hospital because of RSV, making it the most common reason for babies to be admitted to hospital in the first year of life.
Purpose of the study:
The primary purpose of this study is to determine the safety and effectiveness of a study vaccine in the prevention of RSV.
Is my child eligible to participate?
We are looking for healthy children between 12 and 24 months old to take part in a clinical research study.
If after the screening visit, we determine that your child has had RSV infection before then they will not be able to take part in the study.
The study will involve you coming with your child to the Canadian Center for Vaccinology (CCfV) located at IWK Health Center. The study involves 10 visits over a 2-year period. You will be compensated for any out-of-pocket expenses such as travel costs to and from study visits and parking.
Visits will include blood tests, three injections of the study vaccinations (the RSV vaccine, the approved Nimenrix (meningococcal ACWY) vaccine or placebo), nose swabs to see if your child has RSV, physical exams, and questions about your baby’s health by the study nurses and doctors.
Contact Pam MacIntyre